The WinSanTor Solution
A TRUE CURE FOR NEUROPATHY
Unmet Need
Neuropathy affects nearly 1 in 15 Americans. It is one of the largest unmet medical challenges existing today, with no FDA approved treatments outside analgesics.
Breakthrough
We have discovered compounds that prevent and reverse peripheral neuropathy. Our results validate the discovery of a pathway to augment nerve growth and sensory function.
Drive
Who We Are:
Key Opinion Leaders
+ Leading Institutional Stakeholders
+ Proven Management Team
+ World Class Advisors
Strategy
We are focused on managing global resources to accelerate the development of the first effective treatment for patients with peripheral neuropathy.
Meet June
June is an 85-year-old woman who got neuropathy from the radiation treatment for her breast cancer. She has lost feeling in her feet and experiences numbing in her calves. Like so many others, she now has to use a walker.
Recent News
Investors
WinSanTor Inc. is a private biotechnology company focused on the discovery and development of treatments for peripheral neuropathies. WinSanTor recently completed Phase 1 trials for its lead drug, WST-057, and will begin recruiting for its Phase 2 trials in Canada to treat patients with diabetic peripheral neuropathy.